NEWS
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
Veru Inc. presented a meta-analysis of enobosarm's effects on body composition in older obese patients at ObesityWeek 2024. The analysis, based on four previous clinical trials, showed that enobosarm 3mg treatment led to better outcomes compared to placebo. By Day 147, enobosarm-treated subjects showed greater total weight loss (-2.93kg vs -2.11kg placebo), better lean mass preservation (-0.79kg vs -1.77kg placebo), and increased fat mass reduction (-2.05kg vs -0.05kg placebo). The drug was well-tolerated with no increase in gastrointestinal side effects.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment